Developing a prognostic model for hepatocellular carcinoma based on MED19 and clinical stage and determining MED19 as a therapeutic target
These findings suggest that MED19 as a novel biomarker that has significant association with immune landscape and immunotherapy response in HCC. The proposed prediction model composed of MED19 and pathological stage has a better role in determining prognosis and stratifying of HCC.
Authors
- Jialin Sun (ORCID: https://orcid.org/0000-0002-8563-1308)
- Qichun Wei (ORCID: https://orcid.org/0000-0002-8688-5000)
- Danyang Cai
- Wei Hu (ORCID: https://orcid.org/0000-0002-0416-1130)
- Yun Zhang (ORCID: https://orcid.org/0000-0002-8843-6380)
- Chang Liu (ORCID: https://orcid.org/0000-0002-6371-6976)
- Qun Cai (ORCID: https://orcid.org/0000-0002-8457-6976)
- Jin Xiao-jun
Institutions
- Wenzhou Medical University (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
- First Bethune Hospital of Jilin University (CN)
- Ningbo University Affiliated Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Zhejiang Taizhou Hospital (CN)
- East China Normal University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1007/s00432-024-05978-x
- Citations
- 3
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Ningbo Municipal Bureau of Education